title: Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors.
abstract: Epithelial ovarian cancer represents one of the most deadly gynaecological neoplasms in developed countries and is a highly heterogeneous disease. Epidemiological studies show that anti-inflammatory drugs reduce the incidence and mortality of several types of cancer, indicating the potential role of pro-inflammatory factors in carcinogenesis. The expression of pro-inflammatory factors in various cancer types, including ovarian cancer, was assessed in many studies, yielding in consistent results, often due to the histological heterogeneity of various cancers. The aim of the study was to investigate the expression of IL-1, IL-6, TGF-β, TNF-α, COX-2, iNOS, and NF-kB in serous and mucinous ovarian cancers. Ninety cases of ovarian tumors classified into mucous and serous type (45 patients in each group) were selected. Each group was classified into subgroups according to the three stages of tumor differentiation, i.e. into (i) benign, (ii) borderline and (iii) malignant tumors. The presence of proteins of interest in paraffin sections was analysed by immunohistochemistry. The expression of most of the studied factors depended on the histological tumor subtype and the degree of malignancy. Expression of NF-κB appears to be related to the level of the neoplastic differentiation only in the group of serous tumors, while the presence of IL-6 in the mucinous tumor subtype was observed only in the case of benign lesions. Expression of IL-1, TNF-α and COX-2 increased with the stage of the disease in both serous and mucinous tumors. The highest level of TGF-β expression was observed in serous borderline tumors. The different levels of iNOS immunoreactivity between the groups of serous and mucinous tumors were observed only in borderline tumors. The results of our study may be helpful in designing therapeutic strategies depending on the type of ovarian cancer.
authors.forename: Danuta
authors.initials: D
authors.lastname: Plewka
authors.forename: Anna E
authors.initials: AE
authors.lastname: Kowalczyk
authors.forename: Beata
authors.initials: B
authors.lastname: Jakubiec-Bartnik
authors.forename: Michal
authors.initials: M
authors.lastname: Morek
authors.forename: Edyta
authors.initials: E
authors.lastname: Bogunia
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kmiec
authors.forename: Piotr M
authors.initials: PM
authors.lastname: Wierzbicki
authors.affiliation: Department of Proteomics, Medical University of Silesia, Sosnowiec, Poland. aplewka@sum.edu.pl.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Plewka
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000175:diagnosis / Q000201:enzymology / Q000378:metabolism*; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000378:metabolism*
chemical_list: D016207:Cytokines; D016328:NF-kappa B; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human